Released Nov 8, 2024, after the close
10-Q filed Nov 8, 2024, 39 days after period end · 0000950170-24-124036
Q3 2024 · 10-Q
Revenue—
Net Income-$2.24M-$2.24M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$40.15-$40.15 N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$1,796,686N/M
Operating Cash Flowderived-$9,256,984N/M
Free Cash Flowderived-$9,274,672N/M
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Net Income | -$2.24M | -$2.63M | -$1.17M | -$3.04M |
| EPS Diluted | -$40.15 | -$9.94 | -$1.91 | -$0.48 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revelation Biosciences, Inc. · CIK 1810560 · Engraved from SEC EDGAR